Literature DB >> 17397100

Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder.

Patrick Mbaya1, Faouzi Alam, Sindhu Ashim, David Bennett.   

Abstract

OBJECTIVE: To assess cardiovascular safety profile of high dose Venlafaxine XL in patients with major depression.
METHOD: Effects of high dose venlafaxine (mean 346.15 mg;) on the cardiovascular system in 37 patients with major depressive disorder were evaluated: BP, ECG (PR, QT, QRSD and QTc intervals) and heart rate.
RESULTS: 12.5% of patients developed hypertension after starting treatment with venlafaxine. There was an association between heart rate and the dose of venlafaxine although not statistically significant. There was no association between dose of venlafaxine and PR, QT, QRSD and QTc intervals. One patient on 300 mg who was hypertensive and on other medications that may prolong QTc, had mildly prolonged QTc. However this was not clinically significant.
CONCLUSION: This study of subjects on high dose venlafaxine (mean 346.15 mg; range 225-525 mg) did not demonstrate any clinical or statistically significant effects on electrocardiogram (ECG) parameters including PR, QT, QRSD and QTc interval. Copyright 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17397100     DOI: 10.1002/hup.834

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  13 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

Review 2.  Medically serious adverse effects of newer antidepressants.

Authors:  Rajnish Mago; Rajeev Mahajan; Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

3.  Experience of the use of velaxin (venlafaxine) in anxious depression.

Authors:  N A Il'ina
Journal:  Neurosci Behav Physiol       Date:  2009-03

Review 4.  Cardiovascular effects of noncardiovascular drugs.

Authors:  Satish R Raj; C Michael Stein; Pablo J Saavedra; Dan M Roden
Journal:  Circulation       Date:  2009-09-22       Impact factor: 29.690

Review 5.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

6.  A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose.

Authors:  David Taylor; Alan Lenox-Smith; Andrew Bradley
Journal:  Ther Adv Psychopharmacol       Date:  2013-06

7.  Clinical use of antidepressant therapy and associated cardiovascular risk.

Authors:  W Stephen Waring
Journal:  Drug Healthc Patient Saf       Date:  2012-08-17

8.  The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults.

Authors:  Lauren M Behlke; Eric J Lenze; Vy Pham; J Philip Miller; Timothy W Smith; Yasmina Saade; Jordan F Karp; Charles F Reynolds; Daniel M Blumberger; Cristiana Stefan; Benoit H Mulsant
Journal:  J Clin Psychopharmacol       Date:  2020 Nov/Dec       Impact factor: 3.118

Review 9.  Cardiovascular considerations in antidepressant therapy: an evidence-based review.

Authors:  Habibeh Yekehtaz; Mehdi Farokhnia; Shahin Akhondzadeh
Journal:  J Tehran Heart Cent       Date:  2013-10-28

Review 10.  Transcranial direct current stimulation and repetitive transcranial magnetic stimulation in consultation-liaison psychiatry.

Authors:  L C L Valiengo; I M Benseñor; P A Lotufo; R Fraguas; A R Brunoni
Journal:  Braz J Med Biol Res       Date:  2013-10-02       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.